GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
GILEAD SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$153.07−3.12 (-2.00%)
Close on Oct 19, 2026
- Market cap
- $190.27B
- P/E (TTM)
- –
- Dividend yield
- 2.06%
GILEAD SCIENCES, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $28.92B | $28.61B | $26.93B | $26.98B | $27.01B | $24.36B | $22.12B | $21.68B | $25.66B | $29.95B | 98.2% | +1.1% |
| Total HIV | $20.75B | $19.61B | $18.18B | $17.19B | $16.32B | $16.94B | $16.44B | $14.63B | – | – | 70.5% | +5.8% |
| Biktarvy | $14.33B | $13.42B | $11.85B | $10.39B | $8.62B | $7.26B | $4.74B | $1.18B | $0 | $0 | 48.7% | +6.8% |
| Total Oncology | $3.24B | $3.29B | $2.93B | $2.14B | $1.25B | – | – | – | – | – | 11.0% | -1.6% |
| Total Liver Disease | $3.22B | $3.02B | $2.78B | $2.80B | $2.85B | – | – | – | – | – | 10.9% | +6.5% |
| Descovy | $2.76B | $2.11B | $1.99B | $1.87B | $1.70B | $1.86B | $1.50B | $1.58B | $1.22B | $298.00M | 9.4% | +30.5% |
| Total Cell Therapy | $1.84B | $1.97B | $1.87B | $1.46B | $871.00M | $607.00M | $456.00M | $264.00M | – | – | 6.2% | -6.8% |
| Genvoya | $1.50B | $1.76B | $2.06B | $2.40B | $2.88B | $3.34B | $3.93B | $4.62B | $3.67B | $1.48B | 5.1% | -15.0% |
| Yescarta | $1.50B | $1.57B | $1.50B | $1.16B | $695.00M | $563.00M | $456.00M | $264.00M | $7.00M | $0 | 5.1% | -4.8% |
| Trodelvy | $1.40B | $1.32B | $1.06B | $680.00M | $380.00M | $49.00M | $0 | – | – | – | 4.7% | +6.2% |
| Sofosbuvir/Velpatasvir | $1.27B | $1.60B | $1.54B | $1.53B | – | – | – | – | – | – | 4.3% | -20.3% |
| Odefsey | $1.17B | $1.29B | $1.35B | $1.47B | $1.57B | $1.67B | $1.66B | $1.60B | $1.11B | $329.00M | 4.0% | -9.4% |
| Vemlidy | $1.07B | $959.00M | $862.00M | $842.00M | – | – | – | – | – | – | 3.6% | +11.6% |
| Veklury | $911.00M | $1.80B | $2.18B | $3.91B | $5.57B | $2.81B | $0 | – | – | – | 3.1% | -49.4% |
| Other Liver Disease | $874.00M | $467.00M | $385.00M | $426.00M | – | – | – | – | – | – | 3.0% | +87.2% |
| Total Other | $799.00M | $889.00M | $859.00M | $946.00M | $1.03B | $1.03B | $1.55B | $3.10B | – | – | 2.7% | -10.1% |
| Royalty, contract and other revenues | $527.00M | $144.00M | $182.00M | $299.00M | $297.00M | $334.00M | $330.00M | $450.00M | $445.00M | $437.00M | 1.8% | +266.0% |
| AmBisome | $509.00M | $533.00M | $492.00M | $497.00M | $540.00M | $436.00M | $407.00M | $420.00M | $366.00M | $356.00M | 1.7% | -4.5% |
| Other HIV | $500.00M | $434.00M | $401.00M | $530.00M | – | – | – | – | – | – | 1.7% | +15.2% |
| Symtuza - Revenue share | $495.00M | $592.00M | $529.00M | $530.00M | – | – | – | – | – | – | 1.7% | -16.4% |
| Tecartus | $344.00M | $403.00M | $370.00M | $299.00M | $176.00M | $44.00M | $0 | – | – | – | 1.2% | -14.6% |
| Other | $290.00M | $356.00M | $367.00M | $449.00M | $281.00M | $276.00M | $203.00M | $218.00M | $1.18B | $4.21B | 1.0% | -18.5% |
| Intangible Asset - Ranexa [Member] | – | – | – | – | – | – | – | – | $717.00M | $677.00M | – | – |
| Letairis [Member] | – | – | – | – | – | – | – | – | $887.00M | $819.00M | – | – |
| Other Products [Member] | – | – | – | – | – | – | – | – | $207.00M | $188.00M | – | – |
| Ambisome [Member] | – | – | – | – | – | – | – | – | $366.00M | $356.00M | – | – |
| Viread [Member] | – | – | – | – | – | – | – | – | $1.05B | $1.19B | – | – |
| Atripla [Member] | – | – | – | – | – | – | – | – | $1.81B | $2.61B | – | – |
| Antiviral Products [Member] | – | – | – | – | – | – | – | – | $23.34B | $27.75B | – | – |
| Truvada [Member] | – | – | – | – | – | – | – | – | $3.13B | $3.57B | – | – |
| Stribild [Member] | – | – | – | – | – | – | – | – | $1.05B | $1.91B | – | – |
| Complera Eviplera [Member] | – | – | – | – | – | – | – | – | $966.00M | $1.46B | – | – |
| Sovaldi [Member] | – | – | – | – | – | – | – | – | $964.00M | $4.00B | – | – |
| Other antiviral products [Member] | – | – | – | – | – | – | – | – | $196.00M | $72.00M | – | – |
| Harvoni [Member] | – | – | – | – | – | – | – | – | $4.37B | $9.08B | – | – |
| Zydelig [Member] | – | – | – | – | – | – | – | – | $149.00M | $168.00M | – | – |
| Genvoya [Member] | – | – | – | – | – | – | – | – | $3.67B | $1.48B | – | – |
| Epclusa [Member] | – | – | – | – | – | – | – | – | $3.51B | $1.75B | – | – |
| Descovy [Member] | – | – | – | – | – | – | – | – | $1.22B | $298.00M | – | – |
| Odefsey [Member] | – | – | – | – | – | – | – | – | $1.11B | $329.00M | – | – |
| Vosevi [Member] | – | – | – | – | – | – | – | – | $293.00M | $0 | – | – |
| Letairis | – | – | $142.00M | $196.00M | $206.00M | $314.00M | $618.00M | $943.00M | $887.00M | $819.00M | – | – |
| Ranexa | – | – | – | – | $10.00M | $9.00M | $216.00M | $758.00M | $717.00M | $677.00M | – | – |
| Zydelig | – | – | – | – | $62.00M | $72.00M | $103.00M | $133.00M | $149.00M | $168.00M | – | – |
| Other HIV | – | – | $56.00M | $57.00M | $195.00M | $407.00M | $47.00M | $61.00M | $58.00M | $47.00M | – | – |
| Revenue share - Symtuza | – | – | $529.00M | $530.00M | $531.00M | $488.00M | $379.00M | $79.00M | $0 | $0 | – | – |
| Epclusa | – | – | – | – | – | – | – | $1.97B | $3.51B | $1.75B | – | – |
| Harvoni | – | – | – | – | – | – | – | $1.22B | $4.37B | $9.08B | – | – |
| Vosevi | – | – | – | – | – | – | $257.00M | $396.00M | $293.00M | $0 | – | – |
| Atripla | – | – | – | – | $145.00M | $349.00M | $600.00M | $1.21B | $1.81B | $2.61B | – | – |
| Complera/Eviplera | – | – | $129.00M | $200.00M | $258.00M | $269.00M | $406.00M | $653.00M | $966.00M | $1.46B | – | – |
| Stribild | – | – | $101.00M | $127.00M | $189.00M | $196.00M | $369.00M | $644.00M | $1.05B | $1.91B | – | – |
| Truvada | – | – | $114.00M | $147.00M | $371.00M | $1.45B | $2.81B | $3.00B | $3.13B | $3.57B | – | – |
| Other Products, Vemlidy | – | – | – | – | – | $657.00M | $488.00M | $321.00M | $122.00M | $3.00M | – | – |
| Other Products, Viread | – | – | – | – | – | $185.00M | $243.00M | $307.00M | $1.05B | $1.19B | – | – |
| Ledipasvir/Sofosbuvir | – | – | $70.00M | $115.00M | $212.00M | $272.00M | $643.00M | $1.22B | $4.37B | – | – | – |
| Sofosbuvir/Velpatasvir | – | – | $1.54B | $1.53B | $1.46B | $1.60B | $1.97B | $1.97B | $3.51B | – | – | – |
| Veklury | – | – | – | – | – | $2.81B | $0 | $0 | – | – | – | – |
| Other HCV | – | – | $160.00M | $166.00M | $207.00M | $193.00M | $328.00M | $498.00M | – | – | – | – |
| Trodelvy | – | – | – | – | – | $49.00M | $0 | $0 | – | – | – | – |
| Total HCV | – | – | $1.77B | $1.81B | $1.88B | $2.06B | $2.94B | $3.69B | – | – | – | – |
| Tecartus | – | – | – | – | – | $44.00M | $0 | $0 | – | – | – | – |
| Vemlidy | – | – | $862.00M | $842.00M | $814.00M | $657.00M | $488.00M | – | – | – | – | – |
| Other HB/HDV | – | – | $72.00M | $55.00M | $44.00M | $18.00M | $11.00M | – | – | – | – | – |
| Total HBV/HDV | – | – | $1.02B | $988.00M | $969.00M | $860.00M | $742.00M | – | – | – | – | – |
| Viread | – | – | $83.00M | $91.00M | $111.00M | $185.00M | $243.00M | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $20.88B | $20.59B | $19.44B | $18.88B | $19.27B | $18.22B | $16.65B | $16.27B | $18.19B | $19.35B | 70.9% | +1.4% |
| Europe | $5.06B | $4.63B | $4.31B | $4.47B | $4.87B | $4.14B | $3.81B | $4.01B | $5.31B | $6.37B | 17.2% | +9.3% |
| Rest of World | $3.50B | $3.53B | $3.37B | $3.93B | – | – | – | – | – | – | 11.9% | -0.7% |
| Japan | – | – | – | – | – | – | – | – | – | $2.53B | – | – |
| Other Countries [Member] | – | – | – | – | – | – | – | – | $2.60B | $4.67B | – | – |
| Rest of World | – | – | $3.37B | $3.93B | $3.16B | $2.34B | $1.99B | $1.85B | $2.60B | $4.67B | – | – |
From the segment and revenue-disaggregation notes of Gilead Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.